| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Eliquis | $1.88B | $1.62B | $1.83B | $1.92B | $2.00B | $2.02B | $2.02B | $2.17B |
| Prevnar Family | $1.36B | $1.80B | $1.56B | $1.66B | $1.38B | $1.74B | $1.71B | $1.69B |
| Vyndaqel family | $1.32B | $1.45B | $1.54B | $1.49B | $1.62B | $1.59B | $1.69B | $1.60B |
| Ibrance | $1.13B | $1.09B | $1.10B | $977.00M | $1.05B | $1.06B | $1.04B | $1.01B |
| All Other Hospital and Biosimilars | — | — | — | — | — | — | — | $953.00M |
| All other Primary Care | $759.00M | $742.00M | $787.00M | $609.00M | $736.00M | $721.00M | $789.00M | $654.00M |
| Padcev | $394.00M | $409.00M | $444.00M | $426.00M | $542.00M | $464.00M | $508.00M | $591.00M |
| All other Specialty Care | $429.00M | $323.00M | $344.00M | $486.00M | $390.00M | $407.00M | $476.00M | $579.00M |
| Xtandi | $495.00M | $561.00M | $565.00M | $458.00M | $566.00M | $578.00M | $592.00M | $444.00M |
| Oncology Biosimilars | $279.00M | $285.00M | $209.00M | $264.00M | $353.00M | $315.00M | $369.00M | $409.00M |
| Royalty | $345.00M | $384.00M | $431.00M | $308.00M | $426.00M | $436.00M | $480.00M | $396.00M |
| All other Oncology | $347.00M | $268.00M | $285.00M | $377.00M | $380.00M | $272.00M | $303.00M | $376.00M |
| Nurtec ODT/Vydura | $356.00M | $337.00M | $393.00M | $248.00M | $359.00M | $412.00M | $405.00M | $353.00M |
| Lorbrena | $169.00M | $206.00M | $193.00M | $222.00M | $251.00M | $268.00M | $282.00M | $305.00M |
| Pfizer CentreOne | $278.00M | $285.00M | $326.00M | $273.00M | $328.00M | $344.00M | $409.00M | $289.00M |
| Comirnaty | $195.00M | $1.42B | $3.38B | $565.00M | $381.00M | $1.15B | $2.27B | $232.00M |
| Inlyta | $252.00M | $247.00M | $242.00M | $219.00M | $243.00M | $226.00M | $235.00M | $214.00M |
| Sulperazon (Outside the U.S. and Canada) | $144.00M | $156.00M | $169.00M | $164.00M | $166.00M | $154.00M | $169.00M | $199.00M |
| Adcetris | $279.00M | $268.00M | $285.00M | $218.00M | $255.00M | $215.00M | $220.00M | $190.00M |
| Paxlovid | $251.00M | $2.70B | — | $491.00M | $427.00M | $1.23B | — | $186.00M |
| Inflectra | $97.00M | $126.00M | — | $153.00M | $139.00M | $173.00M | — | $182.00M |
| Abrysvo | $56.00M | $356.00M | $198.00M | $131.00M | $143.00M | $279.00M | $480.00M | $180.00M |
| Xeljanz | $303.00M | $321.00M | $350.00M | $128.00M | $322.00M | $313.00M | $324.00M | $180.00M |
| Braftovi/Mektovi | $148.00M | $173.00M | $170.00M | $136.00M | $182.00M | $202.00M | $197.00M | $174.00M |
| Zavicefta (Outside the U.S. and Canada) | $150.00M | $152.00M | $159.00M | $135.00M | $163.00M | $158.00M | $181.00M | $150.00M |
| Enbrel (Outside the U.S. and Canada) | $179.00M | $169.00M | $183.00M | $140.00M | $154.00M | $154.00M | $179.00M | $138.00M |
| Bosulif | $167.00M | $161.00M | $171.00M | $151.00M | $149.00M | $150.00M | $161.00M | $129.00M |
| Tukysa | $121.00M | $124.00M | $129.00M | $102.00M | $132.00M | $110.00M | $119.00M | $122.00M |
| Octagam | $104.00M | $221.00M | $109.00M | $88.00M | $97.00M | $113.00M | $120.00M | $122.00M |
| Zithromax | $74.00M | $83.00M | $123.00M | $158.00M | $56.00M | $73.00M | $113.00M | $112.00M |
| Orgovyx | — | — | — | — | — | $112.00M | $136.00M | $109.00M |
| Genotropin | $119.00M | $119.00M | $112.00M | $95.00M | $106.00M | $128.00M | $117.00M | $93.00M |
| FSME-IMMUN/TicoVac | $100.00M | $81.00M | $34.00M | $63.00M | $109.00M | $100.00M | $47.00M | $81.00M |
| Elrexfio | $22.00M | $40.00M | $57.00M | $60.00M | $85.00M | $85.00M | $74.00M | $80.00M |
| Cibinqo | $47.00M | $63.00M | $63.00M | $58.00M | $69.00M | $79.00M | $78.00M | $76.00M |
| Talzenna | $32.00M | $36.00M | $26.00M | $40.00M | $46.00M | $47.00M | $49.00M | $50.00M |
| Tivdak | $33.00M | $34.00M | $37.00M | $33.00M | $46.00M | $37.00M | $32.00M | $33.00M |
| Total | $13.28B | $17.70B | $17.76B | $13.72B | $14.65B | $16.65B | $17.56B | $14.45B |
Excluding Comirnaty and Paxlovid is derived from annual filings.